Oncologic outcomes of radical prostatectomy in patients with clinical locally advanced prostate cancer

Authors

  • V.M. Grygorenko SE “Institute of Urology NAMS of Ukraine”, Ukraine
  • M.V. Vikarchuk SE “Institute of Urology NAMS of Ukraine”, Ukraine
  • R.O. Danylets SE “Institute of Urology NAMS of Ukraine”, Ukraine
  • O.O. Banas SE “Institute of Urology NAMS of Ukraine”, Ukraine
  • N.V. Brovko SE “Institute of Urology NAMS of Ukraine”, Ukraine
  • S.S. Volkov SE “Institute of Urology NAMS of Ukraine”, Ukraine

DOI:

https://doi.org/10.26641/2307-5279.21.2.2017.149984

Keywords:

locally advanced prostate cancer, radical prostatectomy

Abstract

Oncologic outcomes of radical prostatectomy in 106 patients with clinically locally advanced prostate cancer were demonstrated. The mean patient’s age was 62,1 (40–78) years, mean PSA level – 29,4 (2,5–150) ng/ml. In pathological examination 17,9% of patients had localized prostate cancer, 19,8% – positive lymph nodes. Gleason Score was Ј 6 in 32 (30,2%), 7 – 47 (44,3%), і 8 – in 27 (25,5%) patients. Positive surgical margin were found in 37 (34,9%), perineural invasion of tumor – in 52 (49,1%) patients. The mean follow-up was 50, 6 (12–129) months. 5-year recurrence-free survival was 47,7%, 5-year cancer-specific and overall survival – 85,8%.

References

Arnold M. et al. Recent trends in incidence of five common cancers in 26 European countries since 1988: Analysis of the European Cancer Observatory. – Eur. J. Cancer. – 2015. – V. 51. – P. 1164.

Gnanapragasam V.J., Mason M.D., Shaw G.L., Neal D.E. The role of surgery in high-risk localised prostate cancer. – BJU Int. – 2012. – V. 109. – P. 648–658.

NCCN guidelines on prostate cancer, version 1.2016. National Comprehensive Cancer Network Website: [Электронный ресурс]. URL: http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf .

Wiegel T. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95 / T. Wiegel, D. Bottke, U. Steiner, et al. // J. Clin. Oncol. – 2009. – V. 27 – P. 2924–2930.

Dorff T.B. Adjuvant androgen deprivation for high-risk prostate cancer after radical prostatectomy: SWOG S9921 study / T.B. Dorff, T.W. Flaig, C.M. Tangen et al. // J. Clin. Oncol. – 2011. – V. 29 – P. 2040–2045.

Рак в Україні, бюлетень національного канцер-реєстру України. – К., 1989–2013.

Sobin L.H. International Union against Cancer. 7th ed. 2009 / Sobin L.H., Gospodarowicz M.K., Wittekind Ch. – Chichester, West Sussex, UK; Hoboken, NJ: Wiley-Blackwell, 2010 – P. 243–248.

M.V. Meng, E.P. Elkin, D.M. Latini, J. DuChane, P.R. Carroll. Treatment of patients with high risk localized prostate cancer: results from Cancer of the Prostate Strategic Urological Research Endeavor (CaPSURE) / Journal of Urology. – 2005. – V. 173, N 5. – P. 1557–1561.

H. Van Poppel, S. Joniau. An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer // European Urology. – 2008. – V. 53, N 2. – P. 253–259.

S.I. Martinez de la Rva, J.B. Lуpez-Tomasety, R.M. Domнnguez, E.Б. Cruz, P.S. Blanco. Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up // Archivos Espanoles de Urologia. – 2004. – V. 57, N 7. – P. 679–692.

J.F. Ward, J.M. Slezak, M.L. Blute, E.J. Bergstralh, H. Zincke. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-Year outcome // British Journal of Urology International. – 2005. – V. 95, N 6. – P. 751–756.

Xylinas E., Dachй A., Rouprкt M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? // British Journal of Urology International. – 2010. – V. 106. – P. 1596–1600.

Published

2018-12-07

Issue

Section

Oncourology